BR112013027070A2 - métodos e composições para diminuir expressão de gene utilizando componentes que auto montam em células e produzem atividade de rnai - Google Patents
métodos e composições para diminuir expressão de gene utilizando componentes que auto montam em células e produzem atividade de rnaiInfo
- Publication number
- BR112013027070A2 BR112013027070A2 BR112013027070A BR112013027070A BR112013027070A2 BR 112013027070 A2 BR112013027070 A2 BR 112013027070A2 BR 112013027070 A BR112013027070 A BR 112013027070A BR 112013027070 A BR112013027070 A BR 112013027070A BR 112013027070 A2 BR112013027070 A2 BR 112013027070A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- cells
- methods
- gene expression
- assembling components
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477291P | 2011-04-20 | 2011-04-20 | |
US201161477283P | 2011-04-20 | 2011-04-20 | |
US201161477875P | 2011-04-21 | 2011-04-21 | |
PCT/US2012/034595 WO2012145729A2 (en) | 2011-04-20 | 2012-04-20 | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013027070A2 true BR112013027070A2 (pt) | 2019-09-24 |
Family
ID=47042197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013027070A BR112013027070A2 (pt) | 2011-04-20 | 2012-04-20 | métodos e composições para diminuir expressão de gene utilizando componentes que auto montam em células e produzem atividade de rnai |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150038549A1 (pt) |
EP (1) | EP2699271A4 (pt) |
JP (1) | JP2014519806A (pt) |
CN (1) | CN104271740A (pt) |
AU (1) | AU2012245188A1 (pt) |
BR (1) | BR112013027070A2 (pt) |
CA (1) | CA2871089A1 (pt) |
IL (1) | IL228951A0 (pt) |
RU (1) | RU2013151301A (pt) |
WO (1) | WO2012145729A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970972B1 (en) * | 2013-03-11 | 2018-08-15 | Fondazione Telethon | Mir-204 and mir-211 and uses thereof |
RU2644247C2 (ru) * | 2013-03-15 | 2018-02-08 | Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем | Использование биогенеза микрорнк в экзосомах для диагностики и лечения |
US10119136B2 (en) * | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
WO2015168661A1 (en) * | 2014-05-01 | 2015-11-05 | Smith Larry J | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT |
PL3166607T3 (pl) | 2014-07-11 | 2023-02-20 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych do leczenia hiv |
EP3186378A1 (en) * | 2014-08-27 | 2017-07-05 | Peptimed, Inc. | Anti-tumor compositions and methods |
MA43072A (fr) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
MA42818A (fr) | 2015-09-15 | 2018-07-25 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
TW202321449A (zh) * | 2021-07-07 | 2023-06-01 | 大陸商中美瑞康核酸技術(南通)研究院有限公司 | 用於寡核苷酸劑的基於寡核苷酸的遞送載體及其使用方法 |
WO2024098061A2 (en) | 2022-11-04 | 2024-05-10 | Genkardia Inc. | Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure |
WO2024108217A1 (en) | 2022-11-18 | 2024-05-23 | Genkardia Inc. | Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119212A1 (en) | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
EP2221377B2 (en) | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US20040014957A1 (en) * | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
US6841675B1 (en) | 2002-06-13 | 2005-01-11 | The Regents Of The University Of California | Piperazine-based nucleic acid analogs |
WO2005042719A2 (en) | 2003-10-30 | 2005-05-12 | The Cbr Institute For Biomedical Research, Inc. | Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents |
WO2005074966A1 (en) | 2004-02-06 | 2005-08-18 | Adelaide Research & Innovation Pty. Ltd. | A method of modulating cellular uptake and molecules useful for same |
US20060069050A1 (en) * | 2004-02-17 | 2006-03-30 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
PT2409713E (pt) | 2004-08-10 | 2015-10-09 | Genzyme Corp | Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos |
NZ572403A (en) | 2004-09-24 | 2010-03-26 | Alnylam Pharmaceuticals Inc | Rnai modulation of apob and uses thereof |
DK1799269T3 (en) | 2004-09-28 | 2016-10-03 | Quark Pharmaceuticals Inc | Oligoribonucleotides and methods of use thereof for treating alopecia, acute renal failure, and other diseases |
AU2005306533B2 (en) | 2004-11-17 | 2012-05-31 | Arbutus Biopharma Corporation | siRNA silencing of apolipoprotein B |
EP1934594A2 (en) | 2005-09-07 | 2008-06-25 | Jiang, Xian-cheng | An animal model for studying atherosclerotic lesions |
US7910566B2 (en) | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
ES2471978T3 (es) | 2006-05-05 | 2014-06-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de ApoB |
EP3249052B1 (en) | 2006-05-11 | 2019-04-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the pcsk9 gene |
WO2008033285A2 (en) | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
BRPI0809320A2 (pt) | 2007-03-24 | 2014-09-23 | Genzyme Corp | Método |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
WO2010105096A2 (en) * | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
-
2012
- 2012-04-20 AU AU2012245188A patent/AU2012245188A1/en not_active Abandoned
- 2012-04-20 RU RU2013151301/10A patent/RU2013151301A/ru not_active Application Discontinuation
- 2012-04-20 CN CN201280029769.5A patent/CN104271740A/zh active Pending
- 2012-04-20 CA CA2871089A patent/CA2871089A1/en not_active Abandoned
- 2012-04-20 BR BR112013027070A patent/BR112013027070A2/pt not_active IP Right Cessation
- 2012-04-20 EP EP12774523.0A patent/EP2699271A4/en not_active Withdrawn
- 2012-04-20 US US14/113,093 patent/US20150038549A1/en not_active Abandoned
- 2012-04-20 JP JP2014506610A patent/JP2014519806A/ja active Pending
- 2012-04-20 WO PCT/US2012/034595 patent/WO2012145729A2/en unknown
-
2013
- 2013-10-17 IL IL228951A patent/IL228951A0/en unknown
-
2016
- 2016-04-07 US US15/093,711 patent/US20160272972A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2699271A2 (en) | 2014-02-26 |
RU2013151301A (ru) | 2015-05-27 |
CN104271740A (zh) | 2015-01-07 |
US20150038549A1 (en) | 2015-02-05 |
NZ617944A (en) | 2016-01-29 |
CA2871089A1 (en) | 2012-10-26 |
IL228951A0 (en) | 2013-12-31 |
WO2012145729A3 (en) | 2014-05-01 |
EP2699271A4 (en) | 2015-10-07 |
JP2014519806A (ja) | 2014-08-21 |
AU2012245188A1 (en) | 2013-12-05 |
US20160272972A1 (en) | 2016-09-22 |
WO2012145729A2 (en) | 2012-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013027070A2 (pt) | métodos e composições para diminuir expressão de gene utilizando componentes que auto montam em células e produzem atividade de rnai | |
BR112013024467A2 (pt) | método e composições direcionadas para células adiposas em mamíferos | |
BR112014015562A8 (pt) | aerofólio e método para fabricar um aerofólio | |
BR112014012917A2 (pt) | ácido nucleico recombinante, cassete de expressão, célula, método para obter óleo microbiano, e, óleo microbiano | |
BR112013032559A2 (pt) | cookie em camads saudável | |
BR112012032172A2 (pt) | método para produzir um álcool e composição | |
BR112014020121A2 (pt) | bandeja para uso em uma subarmação de uma armação, métodos para usar uma bandeja e para usar uma subarmação, e, subarmação | |
BR112013032516A2 (pt) | método de biosintetizar butadieno e método para produzir butadieno | |
BR112012009921A2 (pt) | métodos para reprogramar células e usos do mesmos | |
BR112013033711A2 (pt) | processo para fermentar singás e para iniciar fermentador principal para fermentação de singás | |
DK3495498T3 (da) | Genekspressionsanalyse i enkeltceller | |
DK3366775T3 (da) | Modificerede rnai-midler | |
BR112013009483A8 (pt) | estrutura absorvente substancialmente desprovida de celulose para utilização em um artigo absorvente, artigo absorvente e método de fabricação de uma estrutura absorvente | |
BR112013023814A2 (pt) | método para introduzir enzima celulase em pasta de matéria-prima lignocelulósica | |
BR112014006881A2 (pt) | composição para mistura de combustível, mistura de combustível e processo de produção à mistura de combustível | |
BR112014015297A8 (pt) | processamento de biomassa para uso em células de combustável | |
BR112013030209A2 (pt) | métodos baseados em célula e gene para melhorar função cardíaca | |
BR112014003566A2 (pt) | célula hospedeira recombinante, e, método para produzir um ácido c4-dicarboxílico | |
DE112011105920B8 (de) | Brennstoffzellenfahrzeug | |
CU24160B1 (es) | Panel de construcción y metodo de fabricación | |
BR112013026298A2 (pt) | inibidores de micro-rna e seus usos em doenças | |
DK2726201T3 (da) | Reducering af emissioner i polyurethanskum | |
BR112013022254A2 (pt) | método e disposição para gerar oxigênio | |
HK1204653A1 (en) | Method for evaluating redox activity of nucleic acid molecule, and nucleic acid molecule having redox activity | |
BR112014010515A2 (pt) | método para controlar uma população de erva daninha em um ambiente, e, composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |